Search results | lung cancer

Reports

Lung Cancer Partnering

The Lung Cancer Partnering provides understanding and access to the lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Cephalon snags Gemin X for lung cancer drug

Cephalon is once again on the acquisition trail

Industry analysis: Cancer monoclonal antibody partnering on the rise

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Trends analysis: Cancer vaccine partnering on the rise

Recent trends analysis suggests that research in personalized medicine and vaccine development for disease treatment has increased partnering and collaboration in this arena.

Cancer vaccine

A cancer vaccine is a vaccine that treats existing cancer or prevents the development…

Biotech All Stars Buy Castoff Experimental Merck Cancer Drug

Tesaro of Waltham, Mass., a tiny biotech now preparing for its initial public offering, just licensed a promising anti-cancer drug from Merck

UK cancer partners’ R&D spend doubles in a decade

Partners of the UK’s National Cancer Research Institute (NCRI) spent more than £500 million on cancer research last year, nearly double the amount spent almost 10 years ago, says a new report.

Will Respira Health’s offer derail Precision Therapeutic’s licensing of LungExpress Dx?

In an unusual move, Respira Health have tabled a rival licensing proposal for Med BioGene’s LungExpress Dx diagnostic used to improve staging for identifying those patients with early stage non-small-cell lung cancer.

Molecular diagnostics partnering: recent life science trends 2009-2014

Molecular diagnostics is the use of molecular biology for medical testing and clinical applications. This discipline determines how genes and proteins interact in a cell. This partnering article reflects on the recent life science trends in the molecular diagnostics technology arena.

AstraZeneca and Pfizer in the news for another possible m&a bid

AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a  bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.

Top 15 most partnered therapeutic trends in pharma industry

Current Partnering releases its first update of the article previously published last year on the most partnered therapeutic trends in pharma. The article analyses the most partnered therapeutic targets of 2009-2014 and identifies the areas that have gained in popularity since last year and the new areas that have entered the list

Events

Sorry, your search returned no results.


Deals

GSK and Clovis in lung cancer pact

Clovis Oncology have entered into a clinical trial collaboration with GlaxoSmithKline to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC)

GSK pharma partners with Genome Institute of Singapore to further lung cancer research

GlaxoSmithKline, a top 50 pharma company signed a pharma partners collaboration with Genome Institute of Singapore by providing a rant to GIS under the Academic Centre of Excellence to further its research on lung cancer at the institute

Ventana Medical Systems to collaborate with Pfizer and Cell Signaling Technology on companion diagnostic to identify lung cancer patients with ALK gene rearrangements

Ventana Medical Systems has entered into a collaboration agreement with Pfizer to develop the first fully automated and standardized immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements.

Boehringer to manufacture ficlatuzumab for Aveo lung cancer clinical trial

Agreement for large-scale process development and clinical manufacturing of ficlatuzumab

Abbott and Pfizer in pact for lung cancer screening

Abbott will develop a companion diagnostic test that will determine a patient’s genetic status and will be used in patient selection for future clinical trials of PF-02341066.

Eli Lilly, Merck and Pfizer join forces to accelerate research and improve treatment of lung and gastric cancers in Asia

Formation of the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia.

Merck and Syndax partner for cancer combo clinical

Syndax and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining entinostat, an investigational epigenetic therapy, with KEYTRUDA

Eli Lilly and Innovent in pact for three cancer treatments

Eli Lilly and Innovent Biologics announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company

BMS and Celgene become pharma partners for evaluating cancer drugs

Bristol-Myers Squibb and Celgene become a pharma partners for evaluating the efficacy of combination treatment using  OPDIVO and ABRAXANE.

Boehringer Ingelheim in cancer pharma partnering

The National Comprehensive Cancer Network Oncology Research Program recently awarded five research grants in a pharma partnering venture,  to investigators following NCCN ORP Scientific Review Committee analysis of proposals submitted in response to the NCCN Afatinib Request for Proposals.